

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zai Lab Limited

再鼎醫藥有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9688)

INSIDE INFORMATION

THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED THE BIOLOGICS LICENSE APPLICATION FOR VYVGART[®] FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS

This announcement is made by Zai Lab Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company is pleased to announce that China’s National Medical Products Administration has approved the Biologics License Application for VYVGART[®] (efgartigimod alfa injection) (“**VYVGART[®]**”), a first-in-class neonatal Fc receptor (“**FcRn**”) antagonist, as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (“**gMG**”) who are anti-acetylcholine receptor (“**AChR**”) antibody positive. The Company will now work with the National Healthcare Security Administration for National Reimbursement Drug List inclusion for efgartigimod to enable broad access for patients. The Company has an exclusive license agreement with argenx BV to develop and commercialize efgartigimod in mainland China, Hong Kong, Macau, and Taiwan.

ABOUT VYVGART[®]

VYVGART is a human IgG1 antibody fragment that binds to the FcRn, resulting in the reduction of circulating immunoglobulin G (IgG) autoantibodies. It is the first approved FcRn blocker in the United States, EU, and China for the treatment of adults with gMG who are AChR antibody positive, and in Japan for the treatment of adults with gMG who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies.

By Order of the Board

Zai Lab Limited

Samantha Du

Director, Chairperson and Chief Executive Officer

Hong Kong, June 30, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Samantha Du as a director, and Dr. Kai-Xian Chen, Dr. John Diekman, Ms. Nisa Leung, Mr. William Lis, Mr. Leon O. Moulder, Jr., Mr. Peter Wirth, Mr. Scott W. Morrison, Richard Gaynor, M.D. and Mr. Michel Vounatsos as independent directors.

* For identification only